SG10201703964TA - Opioid formulations - Google Patents

Opioid formulations

Info

Publication number
SG10201703964TA
SG10201703964TA SG10201703964TA SG10201703964TA SG10201703964TA SG 10201703964T A SG10201703964T A SG 10201703964TA SG 10201703964T A SG10201703964T A SG 10201703964TA SG 10201703964T A SG10201703964T A SG 10201703964TA SG 10201703964T A SG10201703964T A SG 10201703964TA
Authority
SG
Singapore
Prior art keywords
opioid formulations
opioid
formulations
Prior art date
Application number
SG10201703964TA
Other languages
English (en)
Inventor
Fredrik Tiberg
Ian Harwigsson
Markus Johnsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53487482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201703964T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/558,463 external-priority patent/US20130190341A1/en
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of SG10201703964TA publication Critical patent/SG10201703964TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dental Preparations (AREA)
SG10201703964TA 2012-07-26 2013-07-26 Opioid formulations SG10201703964TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/558,463 US20130190341A1 (en) 2004-06-04 2012-07-26 High bioavailability opioid formulations
US201361806185P 2013-03-28 2013-03-28

Publications (1)

Publication Number Publication Date
SG10201703964TA true SG10201703964TA (en) 2017-06-29

Family

ID=53487482

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201703964TA SG10201703964TA (en) 2012-07-26 2013-07-26 Opioid formulations
SG11201500554XA SG11201500554XA (en) 2012-07-26 2013-07-26 Opioid formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201500554XA SG11201500554XA (en) 2012-07-26 2013-07-26 Opioid formulations

Country Status (20)

Country Link
US (1) US20240075024A1 (zh)
JP (1) JP6417327B2 (zh)
CN (1) CN109010255B (zh)
AU (3) AU2016244271B2 (zh)
CL (1) CL2015000197A1 (zh)
CY (1) CY1124016T1 (zh)
DK (1) DK2877155T3 (zh)
EA (1) EA034855B1 (zh)
ES (1) ES2837803T3 (zh)
HK (2) HK1205948A1 (zh)
HR (1) HRP20210068T1 (zh)
HU (1) HUE053273T2 (zh)
IL (3) IL296882A (zh)
LT (1) LT2877155T (zh)
MX (1) MX361873B (zh)
MY (1) MY189481A (zh)
NZ (2) NZ704012A (zh)
PE (1) PE20150672A1 (zh)
PT (1) PT2877155T (zh)
SG (2) SG10201703964TA (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
WO2019071245A1 (en) * 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
WO2020240018A1 (en) * 2019-05-29 2020-12-03 Camurus Ab Administration device & regime
CN117999079A (zh) * 2021-08-20 2024-05-07 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE401054T1 (de) * 2004-06-04 2008-08-15 Camurus Ab Flüssige depotformulierungen
DK1845942T3 (da) * 2005-01-14 2014-04-28 Camurus Ab GNRH-analogformuleringer
CA2594710C (en) * 2005-01-14 2011-01-25 Camurus Ab Topical bioadhesive formulations
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
IL289157A (en) 2022-02-01
PT2877155T (pt) 2020-12-18
SG11201500554XA (en) 2015-02-27
US20240075024A1 (en) 2024-03-07
MY189481A (en) 2022-02-16
ES2837803T3 (es) 2021-07-01
DK2877155T3 (da) 2021-01-18
IL236762A0 (en) 2015-03-31
JP2015522649A (ja) 2015-08-06
AU2016244271A1 (en) 2016-10-27
AU2019200982B2 (en) 2019-07-18
CY1124016T1 (el) 2022-05-27
AU2017279657B2 (en) 2018-11-15
CL2015000197A1 (es) 2015-11-13
LT2877155T (lt) 2021-02-25
HK1205948A1 (zh) 2015-12-31
EA201590202A1 (ru) 2015-07-30
EA034855B1 (ru) 2020-03-30
AU2019200982A1 (en) 2019-02-28
MX2015001033A (es) 2015-04-09
JP6417327B2 (ja) 2018-11-07
AU2017279657A1 (en) 2018-01-18
CN109010255B (zh) 2022-10-21
MX361873B (es) 2018-12-18
NZ704012A (en) 2017-09-29
PE20150672A1 (es) 2015-05-21
IL296882A (en) 2022-12-01
HRP20210068T1 (hr) 2021-03-05
HK1221636A1 (zh) 2017-06-09
CN109010255A (zh) 2018-12-18
HUE053273T2 (hu) 2021-06-28
NZ735248A (en) 2018-10-26
AU2016244271B2 (en) 2018-01-18
BR112015001548A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
GB201304182D0 (en) No details
GB201403961D0 (en) No details
SI2877155T1 (sl) Opioidne formulacije
GB201411220D0 (en) No details
HK1202445A1 (zh) 新製劑
IL289157A (en) Opioid compounds
HK1205679A1 (zh) 尼古丁製劑
PT2908835T (pt) Formulações estáveis
GB201313844D0 (en) No details
PL2908859T3 (pl) Formulacje arypiprazolu
GB201403415D0 (en) No details
GB201110278D0 (en) Formulations
IL234771B (en) Nicotine formulation
GB201206178D0 (en) Formulations
GB201211247D0 (en) Improved formulation
GB201322955D0 (en) No details
GB201400108D0 (en) No details
GB201302155D0 (en) No details
GB201300109D0 (en) No details
GB201310646D0 (en) No details
GB201220529D0 (en) No details available
GB201107627D0 (en) Formulations
GB201107626D0 (en) Formulations
GB201105410D0 (en) Formulations
GB201105360D0 (en) Formulations